KRAS and colorectal carcinoma: Interestingly, tetrac treatment significantly increased the S-phase cell population from 8.7% (control) to 14.0% in HT-29 cells (KRAS WT CRC) and from 13.7% (control) to 16.8% in HCT-116 cells (KRAS MT CRC) (Figure 2A,B).